-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-68498 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-68498 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-68498 in Triple-Negative Breast Cancer (TNBC) Drug Details:HEC-68498 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HEC-585 in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HEC-585 in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HEC-585 in Interstitial Lung Diseases (Diffuse Parenchymal Lung...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Yinlitinib in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Yinlitinib in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Yinlitinib in Breast Cancer Drug Details: Yinlitinib is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LM-302 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Gastric Cancer Drug Details: LM-302 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LM-302 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: LM-302 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LOXO-338 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in Mantle Cell Lymphoma Drug Details: LOXO-338 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ningetinib Toluenesulfonate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ningetinib Toluenesulfonate in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ningetinib Toluenesulfonate in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Refractory Multiple Myeloma Drug Details: NKTR-255 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-400 in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-400 in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-400 in Uterine Cancer Drug Details: ABBV-400 is under development for...